Recently, the notice by the Science Technology Department of Zhejiang Province of issuing the List of New Types of Research and Development Institutions in 2021, TYK medicines, Inc was recognized as a New Type of Research and Development institution, which integrates the high-end innovation resource and attracted high-level innovation team to conduct the key technology research, support the industrial upgrade, accelerate the transformation of science and technology. The platform is the innovation carrier supported by the country and plays an important role in promoting industrial transformation and upgrading. The selection of TYK Medicines as a provincial-level new type R&D institution in Zhejiang Province is of positive significance for the company to actively explore the new mode of original innovation to industrialization, carry out forward-looking and leading scientific and technological research and key common technology research, promote the close integration of innovation chain, industrial chain, and capital chain, and promote the high-quality development of scientific and technological innovation.

TYK Medicines, Inc strives to build a new type of research and development institution with a trinity of R&D center, talent pool, and think tank, which closely follows the development model based on “innovation-driven, enterprise-driven, and capital-catalyzed”, and strives to become a leading company in the field of biomedicine in the province.

In terms of platform construction, TYK Medicines has established four new drug R&D technology platforms: a new small molecule drug design and screening platform based on targets, a breakthrough blood-brain barrier drug discovery platform, a PROTAC technology platform, an AI&CADD-aided drug design platform. And it is approved as Huzhou Academician Expert Workstation, Huzhou Science and Technology Enterprise Research and Development Center.

In terms of talent introduction, TYK Medicines has introduced 150 scientific research talents of various types, 70% of whom have a master’s degree or above or senior professional titles, and 8 high-level introduced talents including 1 national-level introduction talent, 4 provincial-level introduction talents, and 3 provincial overseas engineers. The company’s innovative team was shortlisted for the “South Taihu Lake Elite Program” of Huzhou city as an innovative leading team. As for now, TYK Medicines has formed a strong R&D lineup of the whole industrial chain of innovative drug R&D from new drug design, new drug screening, new drug synthesis, clinical trial research, and production.

In terms of scientific research, nearly 200 million yuan has been invested in research and development, and more than 10 targeted anti-tumor new drug projects have been carried out. Among them, 1 national chemical 1.1 new drug project has obtained clinical approval from the US FDA, and 2 national chemical 1.1 new drug projects are currently in the stage of clinical trials, and the contracted enterprise horizontal projects are as high as 159 million yuan. The company has applied for 41 new drug-related invention patents and 8 PCT patents, of which 6 domestic patents have been authorized and 1 US patent has been authorized.

In terms of outcomes, in 2020, TYK Medicine has been awarded as the key R&D project (Merit-based project) in Zhejiang Province, the special biomedical project in Huzhou City, and the key technological innovation project in Zhejiang Province. In 2021, two innovative drug projects were selected as foreign expert projects by the Ministry of Science and Technology of China.